Literature DB >> 25327444

Effects of buspirone and the dopamine D3 receptor compound PG619 on cocaine and methamphetamine self-administration in rhesus monkeys using a food-drug choice paradigm.

William S John1, Ashwini K Banala, Amy H Newman, Michael A Nader.   

Abstract

RATIONALE: The dopamine (DA) D2 and D3 receptors have been associated with cocaine abuse. A recent study with the D3 receptor (D3R) partial agonist PG619 found that it attenuated cocaine-induced reinstatement and the D2-like receptor antagonist buspirone has shown positive outcomes in two studies of cocaine abuse in monkeys. However, a recent clinical trial indicated that buspirone did not improve abstinence in treatment-seeking cocaine abusers.
OBJECTIVE: The objective of the study was to examine PG619 and buspirone under a food-drug choice paradigm in order to better model the clinical findings. In addition, we extended the characterization of both compounds to include methamphetamine (MA) self-administration (SA).
METHODS: Six adult male rhesus monkeys were trained to respond under a concurrent food (1.0-g pellets) and drug (0.01-0.3 mg/kg/injection cocaine or MA) choice paradigm in which complete SA dose-response curves were determined each session (N = 3/group). Monkeys received 5 days of treatment with either PG619 (0.1-3.0 mg/kg, i.v.) or buspirone (0.01-1.0 mg/kg, i.m.). In a follow-up study, the SA doses were reduced (0.003-0.1 mg/kg/injection) to increase reinforcement frequency and buspirone was retested.
RESULTS: PG619 did not affect cocaine or MA choice, while buspirone increased low-dose cocaine choice. Changing the SA doses increased the number of reinforcers received each session, but buspirone did not decrease drug choice.
CONCLUSIONS: Consistent with clinical findings, these results do not support the use of buspirone for psychostimulant abuse and suggest that food-drug choice paradigms may have greater predictive validity than the use of other schedules of reinforcement.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25327444      PMCID: PMC4754084          DOI: 10.1007/s00213-014-3760-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.

Authors:  Jennifer L Martelle; Renee Claytor; Jason T Ross; Beth A Reboussin; Amy Hauck Newman; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2007-02-01       Impact factor: 4.030

3.  Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.

Authors:  Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2013-08-07       Impact factor: 7.853

4.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

5.  Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats.

Authors:  P Munzar; S R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2000-02       Impact factor: 4.530

6.  Effects of acute topiramate dosing on methamphetamine-induced subjective mood.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Lynda T Wells; Christopher L Wallace; Michael A Dawes; Lei Liu; Xin-Qun Wang
Journal:  Int J Neuropsychopharmacol       Date:  2006-02-01       Impact factor: 5.176

7.  The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Donna M Platt; Amy H Newman; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2009-06-10       Impact factor: 4.530

8.  Effects of chronic buspirone treatment on cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

9.  Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.

Authors:  Theresa M Winhusen; Frankie Kropp; Robert Lindblad; Antoine Douaihy; Louise Haynes; Candace Hodgkins; Karen Chartier; Kyle M Kampman; Gaurav Sharma; Daniel F Lewis; Paul VanVeldhuisen; Jeff Theobald; Jeanine May; Gregory S Brigham
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

10.  Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Adv Pharmacol Sci       Date:  2012-11-28
View more
  28 in total

1.  Effects of oral and intravenous administration of buspirone on food-cocaine choice in socially housed male cynomolgus monkeys.

Authors:  Paul W Czoty; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

2.  Effects of 7-day continuous D-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys.

Authors:  Kathryn L Schwienteck; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2015-09-02       Impact factor: 4.492

3.  Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.

Authors:  Matthew L Banks; Blake A Hutsell; Kathryn L Schwienteck; S Stevens Negus
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

4.  Effects of the mGluR2/3 receptor agonist LY379268 on the reinforcing strength of cocaine in rhesus monkeys.

Authors:  Paul W Czoty; Bruce E Blough; Antonio Landavazo; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2019-11-09       Impact factor: 4.530

Review 5.  Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.

Authors:  Frank N Perkins; Kevin B Freeman
Journal:  Pharmacol Biochem Behav       Date:  2017-06-27       Impact factor: 3.533

6.  Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.

Authors:  Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2016-05-27       Impact factor: 4.492

7.  Chronic Δ9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability.

Authors:  William S John; Thomas J Martin; Kiran Kumar Solingapuram Sai; Susan H Nader; H Donald Gage; Akiva Mintz; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2017-12-04       Impact factor: 4.030

Review 8.  Cocaine choice procedures in animals, humans, and treatment-seekers: Can we bridge the divide?

Authors:  Scott J Moeller; William W Stoops
Journal:  Pharmacol Biochem Behav       Date:  2015-09-30       Impact factor: 3.533

9.  Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Authors:  Megan M Kangiser; Linda P Dwoskin; Guangrong Zheng; Peter A Crooks; Dustin J Stairs
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

10.  Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.

Authors:  Erika Pike; William W Stoops; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.